SCHEMBL4888041

SCHEMBL4888041

CCCCCCCCCCCCn1cnc2ccccc21

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.68
SMN1; SMN2 Q16637 7/20 0.63
LMNA P02545 4/20 0.63
ALOX15 P16050 1/20 0.63
TSHR P16473 1/20 0.63
HTT P42858 4/20 0.61
MAPT P10636 3/20 0.61
STAT3 P40763 1/20 0.61
MEN1 O00255 2/20 0.59
KMT2A Q03164 2/20 0.59
NPC1 O15118 1/20 0.55
NFKB1 P19838 1/20 0.55
RAB9A P51151 1/20 0.55
NFKB2 Q00653 1/20 0.55
RELA Q04206 1/20 0.55
SLC9A1 P19634 2/20 0.54
EGLN3 Q9H6Z9 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
DRD2 P14416 1/20 0.52
DRD4 P21917 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9853294 1.00 TDP1 (0.68) TDP1SMN1; SMN2LMNAALOX15TSHR
SCHEMBL3868979 1.00 TDP1 (0.68) TDP1SMN1; SMN2LMNAALOX15TSHR
SCHEMBL595111 1.00 TDP1 (0.68) TDP1SMN1; SMN2LMNAALOX15TSHR
SCHEMBL9038339 1.00 TDP1 (0.68) TDP1SMN1; SMN2LMNAALOX15TSHR
SCHEMBL9038701 1.00 TDP1 (0.68) TDP1SMN1; SMN2LMNAALOX15TSHR
SCHEMBL6321085 1.00 TDP1 (0.68) TDP1SMN1; SMN2LMNAALOX15TSHR
SCHEMBL11408718 1.00 TDP1 (0.68) TDP1SMN1; SMN2LMNAALOX15TSHR
SCHEMBL9853336 1.00 TDP1 (0.68) TDP1SMN1; SMN2LMNAALOX15TSHR
SCHEMBL16097150 1.00 TDP1 (0.68) TDP1SMN1; SMN2LMNAALOX15TSHR
SCHEMBL9853222 1.00 TDP1 (0.68) TDP1SMN1; SMN2LMNAALOX15TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0262343-B1 N-alkylated quaternary nitrogen-containing heterocycles, process for their preparation and their use in pharmaceutical compositions PUETTER MEDICE CHEM PHARM (DE) 1996-01-03 EP claimed
WO-2024181373-A1 METHOD FOR SELECTIVELY MODIFYING SUBSTRATE SURFACE, METHOD FOR PRODUCING SURFACE-TREATED SUBSTRATE, AND COMPOSITION JSR株式会社 2024-09-06 WO disclosed
CN-114106788-B Industrial circulating cooling liquid 湖南省希润弗高分子新材料有限公司 2024-07-26 CN disclosed
US-20240174583-A1 PROCESSES FOR THE VAPOR PHASE HYDROGENATION OF ALDEHYDES DOW TECHNOLOGY INVESTMENTS LLC (US) 2024-05-30 US disclosed
EP-4347544-A1 PROCESSES FOR THE VAPOR PHASE HYDROGENATION OF ALDEHYDES Dow Technology Investments LLC (US) 2024-04-10 EP disclosed
CN-117242047-A Process for the vapor phase hydrogenation of aldehydes 陶氏技术投资有限责任公司 2023-12-15 CN disclosed
US-20230295368-A1 CATALYST FOR DISSOCIATION OF BLOCKING AGENT FOR BLOCKED ISOCYANATES, AND THERMOSETTING COMPOSITION CONTAINING SAID CATALYST FOR DISSOCIATION OF BLOCKING AGENT KOEI CHEMICAL COMPANY, LIMITED (JP) 2023-09-21 US disclosed
CN-114158560-B Bactericide for industrial cooling water 湖南省希润弗高分子新材料有限公司 2023-09-01 CN disclosed
US-11718704-B2 Catalyst for dissociation of blocking agent for blocked isocyanates, and thermosetting composition containing said catalyst for dissociation of blocking agent KOEI CHEMICAL COMPANY, LIMITED (JP) 2023-08-08 US disclosed
WO-2022250790-A1 PROCESSES FOR THE VAPOR PHASE HYDROGENATION OF ALDEHYDES DOW TECHNOLOGY INVESTMENTS LLC (US) 2022-12-01 WO disclosed
EP-2970074-A1 HETEREOCYCLIC AGENT AS CATALYTIC STABILIZING AGENT IN A HYDROFORMYLATION PROCESS Dow Technology Investments LLC (US) 2016-01-20 EP disclosed
US-20150376101-A1 HETEREOCYCLIC AGENT AS CATALYTIC STABILIZING AGENT IN A HYDROFORMYLATION PROCESS UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY LLC 2015-12-31 US disclosed
WO-2014149915-A1 HETEREOCYCLIC AGENT AS CATALYTIC STABILIZING AGENT IN A HYDROFORMYLATION PROCESS DOW TECHNOLOGY INVESTMENTS LLC (US) 2014-09-25 WO disclosed
US-20080064898-A1 Method for Producing Oxygen-Containing Compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2008-03-13 US disclosed
EP-1797953-A1 PROCESS FOR PRODUCING OXYGENIC COMPOUND Sumitomo Chemical Company, Limited (JP) 2007-06-20 EP disclosed
EP-0873292-B1 IMPROVED METAL-LIGAND COMPLEX CATALYZED PROCESSES UNION CARBIDE CHEM PLASTIC (US) 2001-12-19 EP disclosed
EP-0873292-A1 IMPROVED METAL-LIGAND COMPLEX CATALYZED PROCESSES UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) 1998-10-28 EP disclosed
US-5731472-A HETEROCYCLIC NITROGEN COMPOUNDS UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) 1998-03-24 US disclosed
WO-1997020798-A1 IMPROVED METAL-LIGAND COMPLEX CATALYZED PROCESSES UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) 1997-06-12 WO disclosed
US-4460709-A Process for producing oxygen-containing organic compounds AGENCY OF INDUSTRIAL SCIENCE & TECHNOLOGY (JP) 1984-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064898-A1 Method for Producing Oxygen-Containing Compound AOC2, AOX1, CAT TDP1 4391/4885SMN1; SMN2 882/4885LMNA 3622/4885
US-20150376101-A1 HETEREOCYCLIC AGENT AS CATALYTIC STABILIZING AGENT IN A HYDROFORMYLATION PROCESS NUDT1, CAT, HRAS TDP1 2238/4885SMN1; SMN2 884/4885LMNA 2254/4885
US-20230295368-A1 CATALYST FOR DISSOCIATION OF BLOCKING AGENT FOR BLOCKED ISOCYANATES, AND THERMOSETTING COMPOSITION CONTAINING SAID CATALYST FOR DISSOCIATION OF BLOCKING AGENT IDH3A, RCOR1, MUS81 TDP1 2293/4885SMN1; SMN2 2445/4885LMNA 3018/4885
US-11718704-B2 Catalyst for dissociation of blocking agent for blocked isocyanates, and thermosetting composition containing said catalyst for dissociation of blocking agent IDH3A, RCOR1, MUS81 TDP1 2293/4885SMN1; SMN2 2445/4885LMNA 3018/4885
US-20240174583-A1 PROCESSES FOR THE VAPOR PHASE HYDROGENATION OF ALDEHYDES ADH1C, ADH5, ALDH2 TDP1 1008/4885SMN1; SMN2 1192/4885LMNA 1542/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.